Report Detail
Global Immune Thrombocytopenia Drugs Market Size, Status and Forecast 2019-2025
- RnM3674274 |
- 16 August, 2019 |
- Global |
- 93 Pages |
- QYResearch |
- Pharma & Healthcare
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
In 2018, the global Immune Thrombocytopenia Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Immune Thrombocytopenia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Thrombocytopenia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
...
Market segment by Type, the product can be split into
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs
Market segment by Application, split into
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Immune Thrombocytopenia Drugs status, future forecast, growth opportunity, key market and key players.
To present the Immune Thrombocytopenia Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Immune Thrombocytopenia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Thrombopoietin Receptor Agonists (TPO-RAs)
- 1.4.3 Corticosteroids
- 1.4.4 Intravenous Immunoglobins (IVIGs)
- 1.4.5 Other Drugs
- 1.5 Market by Application
- 1.5.1 Global Immune Thrombocytopenia Drugs Market Share by Application (2019-2025)
- 1.5.2 Biotechnology and Pharmaceutical Companies
- 1.5.3 Hospitals and Diagnostic Centers
- 1.5.4 Academic Institutes and Research Organizations
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Immune Thrombocytopenia Drugs Market Size
- 2.2 Immune Thrombocytopenia Drugs Growth Trends by Regions
- 2.2.1 Immune Thrombocytopenia Drugs Market Size by Regions (2019-2025)
- 2.2.2 Immune Thrombocytopenia Drugs Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
- 3.1 Immune Thrombocytopenia Drugs Market Size by by Players
- 3.1.1 Global Immune Thrombocytopenia Drugs Revenue by by Players (2014-2019)
- 3.1.2 Global Immune Thrombocytopenia Drugs Revenue Market Share by by Players (2014-2019)
- 3.1.3 Global Immune Thrombocytopenia Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Immune Thrombocytopenia Drugs Key Players Head office and Area Served
- 3.3 Key Players Immune Thrombocytopenia Drugs Product/Solution/Service
- 3.4 Date of Enter into Immune Thrombocytopenia Drugs Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Immune Thrombocytopenia Drugs Market Size by Type (2014-2019)
- 4.2 Global Immune Thrombocytopenia Drugs Market Size by Application (2014-2019)
5 North America
- 5.1 North America Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 5.2 Immune Thrombocytopenia Drugs Key Players in North America
- 5.3 North America Immune Thrombocytopenia Drugs Market Size by Type
- 5.4 North America Immune Thrombocytopenia Drugs Market Size by Application
6 Europe
- 6.1 Europe Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 6.2 Immune Thrombocytopenia Drugs Key Players in Europe
- 6.3 Europe Immune Thrombocytopenia Drugs Market Size by Type
- 6.4 Europe Immune Thrombocytopenia Drugs Market Size by Application
7 China
- 7.1 China Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 7.2 Immune Thrombocytopenia Drugs Key Players in China
- 7.3 China Immune Thrombocytopenia Drugs Market Size by Type
- 7.4 China Immune Thrombocytopenia Drugs Market Size by Application
8 Japan
- 8.1 Japan Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 8.2 Immune Thrombocytopenia Drugs Key Players in Japan
- 8.3 Japan Immune Thrombocytopenia Drugs Market Size by Type
- 8.4 Japan Immune Thrombocytopenia Drugs Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 9.2 Immune Thrombocytopenia Drugs Key Players in Southeast Asia
- 9.3 Southeast Asia Immune Thrombocytopenia Drugs Market Size by Type
- 9.4 Southeast Asia Immune Thrombocytopenia Drugs Market Size by Application
10 India
- 10.1 India Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 10.2 Immune Thrombocytopenia Drugs Key Players in India
- 10.3 India Immune Thrombocytopenia Drugs Market Size by Type
- 10.4 India Immune Thrombocytopenia Drugs Market Size by Application
11 Central & South America
- 11.1 Central & South America Immune Thrombocytopenia Drugs Market Size (2014-2019)
- 11.2 Immune Thrombocytopenia Drugs Key Players in Central & South America
- 11.3 Central & South America Immune Thrombocytopenia Drugs Market Size by Type
- 11.4 Central & South America Immune Thrombocytopenia Drugs Market Size by Application
12 International Players Profiles
- 12.1 Amgen Inc.
- 12.1.1 Amgen Inc. Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Immune Thrombocytopenia Drugs Introduction
- 12.1.4 Amgen Inc. Revenue in Immune Thrombocytopenia Drugs Business (2014-2019))
- 12.1.5 Amgen Inc. Recent Development
- 12.2 CSL Ltd.
- 12.2.1 CSL Ltd. Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Immune Thrombocytopenia Drugs Introduction
- 12.2.4 CSL Ltd. Revenue in Immune Thrombocytopenia Drugs Business (2014-2019)
- 12.2.5 CSL Ltd. Recent Development
- 12.3 Horizon Therapeutics Plc
- 12.3.1 Horizon Therapeutics Plc Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Immune Thrombocytopenia Drugs Introduction
- 12.3.4 Horizon Therapeutics Plc Revenue in Immune Thrombocytopenia Drugs Business (2014-2019)
- 12.3.5 Horizon Therapeutics Plc Recent Development
- 12.4 Merck & Co., Inc.
- 12.4.1 Merck & Co., Inc. Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Immune Thrombocytopenia Drugs Introduction
- 12.4.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenia Drugs Business (2014-2019)
- 12.4.5 Merck & Co., Inc. Recent Development
- 12.5 Novartis AG
- 12.5.1 Novartis AG Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Immune Thrombocytopenia Drugs Introduction
- 12.5.4 Novartis AG Revenue in Immune Thrombocytopenia Drugs Business (2014-2019)
- 12.5.5 Novartis AG Recent Development
- 12.6 Rigel Pharmaceuticals Inc.
- 12.6.1 Rigel Pharmaceuticals Inc. Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Immune Thrombocytopenia Drugs Introduction
- 12.6.4 Rigel Pharmaceuticals Inc. Revenue in Immune Thrombocytopenia Drugs Business (2014-2019)
- 12.6.5 Rigel Pharmaceuticals Inc. Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Product (2019-2025)
- 13.2 Market Size Forecast by Application (2019-2025)
- 13.3 Market Size Forecast by Regions
- 13.4 North America
- 13.5 Europe
- 13.6 China
- 13.7 Japan
- 13.8 Southeast Asia
- 13.9 India
- 13.10 Central & South America
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 15.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Immune Thrombocytopenia Drugs. Industry analysis & Market Report on Immune Thrombocytopenia Drugs is a syndicated market report, published as Global Immune Thrombocytopenia Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Immune Thrombocytopenia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
